SUIC Worldwide Holdings Stock (OTC: SUIC)

Latest news for SUIC Worldwide Holdings (OTC:SUIC) Stock

SUIC Worldwide Holdings Ltd provides research and development, venture financing for, and investing in private enterprises and the public sector that develops products and services adopting core capabilities of the Internet of Things, cloud computing, mobile payment, Big Data, Blockchain, and Artificial Intelligence, to enhance and streamline existing processes, and establish new and exciting business models that will create revolutionary products and services. The company works in several new business ventures with a focus on the following fields; Fintech, Food Industry Supply Chain Integration, Global Chain & Franchise Expansion, and Other Supply Chain Integration.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ABWN

AGTK

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

AQMS

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATHX

ARTEMIS THERAPEUTICS INC by Artemis Therapeutics, Inc.

ATMS

ATYG

BGFT

BLOZF

BOIRF

BWLVF

CBRI

CCGN

CHMR

CMGHF

COCP

CORV

COTE

CSPUF

DVLY

DYLLF

ECOR

ELGX

FERL

FINCANNA CAPITAL CORP by Fincanna Capital Corp.

FNNZF

FUAPF

FVGCF

FVVSF

GGBXF

GLBS

GTBP

GURE

HEMP

HESG

HGEN

HKTTF

HUABF

HVBTF

ICABY

IPSEY

ISIG

IWSY

KINS

KRKR

LATF

LFUGF

LFUGY

MCET

MDIN

MGXMF

MIST

MLXEF

MMJJF

MOAEF

NHNKY

NIMU

NXTTF

OCANF

OGDCF

OLVRF

PARNF

PHAT

PHTCF

PHUN

PMSO

PRTR

PSIX

QBAN

QEGY

QOIL

RETC

RKAGY

RTTR

RVLT

SEED

SEEK

SFEG

SING

SNNAF

SPVNF

SUIC

TBEV

TGIFF

TLGN

TLRY

TOCA

TRPX

TWMC

UBQU

UVSE

VFRM

VGGOF

VREOF

VVCIF

WDDMF

WHITF

ICC INTL CANNABIS CORP by ICC Intl Cannabis Corp.

WLDCF

Stocks That Hit 52-Week Lows On Wednesday

SUIC WORLDWIDE HOLDINGS by SUIC Worldwide Holdings Ltd

SUIC Worldwide Holdings Ltd

Raymond James analyst Andy Marok reiterates Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Outperform and raises the price target from $19 to $21.

Price Target

Reiteration

Analyst Ratings

GRND

Raymond James Reiterates Outperform on Grindr, Raises Price Target to $21

Keybanc analyst Eric Gonzalez downgrades Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) from Overweight to Sector Weight and maintains the price target from $115 to $115.

Downgrades

Keybanc Downgrades Brinker International to Sector Weight, Maintains Price Target to $115

Raymond James analyst Patrick Brown reiterates CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Outperform and lowers the price target from $38 to $37.

Raymond James Reiterates Outperform on CSX, Lowers Price Target to $37

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Alphabet Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google and Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) remain divided in <a target="_blank" href="https://www.benzinga.com/topic/tiktok" rel="noreferrer noopener">their approaches to</a> TikTok as their vested interests play out.
TikTok&#8217;s cloud service provider, Oracle hailed Trump&#8217;s potential softer take on the ByteDance social media platform. Meanwhile, the app remains unavailable in Apple and Google&#8217;s app stores to comply with the January 19 ban, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-01-24/oracle-apple-google-diverge-on-whether-to-keep-serving-tiktok?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">reports</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/01/43110753/aws-robotics-prime-video-ads-fuel-amazon-growth-potential-analysts" rel="noreferrer noopener">AWS, Robotics, Prime Video Ads Fuel Amazon Growth Potential: Analysts</a>
Oracle&#8217;s proximity with Trump and its business relations with TikTok give it enough reasons to assume potential legal risk.
Apple and Google, meanwhile, make minimal revenue from TikTok via in-app purchases compared to any potential fine they may face for violating the law, the report said.
Meanwhile, daily fines for supporting TikTok could climb into the billions of dollars.
According to the Bloomberg report, Oracle leaders have been conservative politics loyalists. CEO Safra Catz served on Trump&#8217;s transition team after the 2016 presidential election, and co-founder and Chairman&nbsp;Larry Ellison&nbsp;has donated to Republicans, including Trump.
Oracle&#8217;s proximity to Trump has paid off in the past. The cloud giant was&nbsp;Trump&#8217;s original pick to buy TikTok&nbsp;in 2020 when he tried to ban the app, citing national security reasons.
Though the deal ultimately fell apart after Trump left office, Oracle became TikTok&#8217;s cloud service provider under a compelling deal.
Ellison is also famously close to Trump&#8217;s ally, Elon Musk. Musk and Ellison&nbsp;have emerged as <a target="_blank" href="https://www.benzinga.com/general/social-media/25/01/43181940/elon-musk-or-larry-ellison-dan-ives-on-who-could-win-tiktoks-billion-dollar-soap-opera-someone-hand-picked-from-beijing-but-also-trumps-white-house" rel="noreferrer noopener">potential contenders for</a> the TikTok acquisition, which could be the popular social media&#8217;s gateway to a $1 trillion valuation. Trump has expressed support for both of them.
Wedbush&#8217;s&nbsp;Dan Ives projected the sale, excluding its algorithm, could be worth $40 billion—$50 billion, possibly attracting 10 to 12 bidders.
On Monday, Trump suspended the TikTok ban for 75 days, creating a window for potential buyers.
Price Actions: At last check on Friday, ORCL stock was down 0.85% at $184.81. AAPL is down 0.21%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/media/25/01/43107710/amazon-pauses-drone-deliveries-in-texas-arizona-after-crashes-plans-safety-upgrades" target="_blank" rel="noreferrer noopener">Amazon Pauses Drone Deliveries In Texas, Arizona After Crashes, Plans Safety Upgrades</a></li>
</ul>
Image via Shutterstock

Government

Regulations

Tech

Media

AAPL

GOOG

GOOGL

ORCL

TikTok Ban Sparks Divide: Oracle Backs Trump While Apple, Google Play It Safe

On Friday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Eisai Co Ltd&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESAIY#OTC">ESAIY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALF#OTC">ESALF</a>) announced results from the Phase 3 LEAP-015 trial of Keytruda (pembrolizumab) plus Lenvima&nbsp;(lenvatinib), in combination with chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative <a href="https://www.benzinga.com/quote/MRK" target="_blank" rel="noreferrer noopener">gastroesophageal adenocarcinoma</a>.
Gastroesophageal adenocarcinoma is a rare type of cancer that occurs in the esophagus, the passageway that connects the mouth and stomach.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43166965/senate-hearings-loom-as-robert-f-kennedy-faces-scrutiny-over-conflicts-of-interest-in-mercks-gardasil-vaccine-litigation" rel="noreferrer noopener">RJK Jr.&#8217;s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing</a>
At an interim analysis, the Keytruda plus Lenvima-based regimen demonstrated a statistically significant improvement in progression-free survival (PFS), one of the study&#8217;s dual primary endpoints, and objective response rate (ORR), a key secondary endpoint, compared to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43187039/merck-and-eisai-provide-update-on-phase-3-leap-015-trial-evaluating-keytruda-pembrolizumab-plus-le" rel="noreferrer noopener">standard of care chemotherapy</a>.
The study continued, and at the final analysis, it did not meet its other primary endpoint of overall survival (OS).
The safety profile of the Keytruda plus Lenvima-based regimen was consistent with that observed in previously reported studies evaluating the combination.
A full evaluation of the data from this study is ongoing, and Merck and Eisai will present these results at an upcoming medical meeting.
Keytruda plus Lenvima is approved in the U.S., the EU, Japan and other countries for advanced renal cell carcinoma (RCC) and certain types of advanced endometrial carcinoma.
In September last year, two Phase 3 trials, LEAP-006 and LEAP-008, evaluating Keytuda plus Lenvima in patients with certain types of metastatic&nbsp;non-small cell lung cancer failed to meet their dual primary endpoints of overall survival (OS) and <a target="_blank" href="https://www.benzinga.com/general/biotech/23/09/34821673/merck-eisai-partnered-two-keytrudalenvima-combo-trials-flunk-in-certain-types-of-lung-cancer" rel="noreferrer noopener">progression-free survival (PFS)</a>.
In August, at the second analysis, Keytruda Lenvima did not demonstrate an improvement in overall survival (OS) in head and neck cancer compared to Keytruda plus placebo, and Merck and Eisai evaluated the likelihood of reaching the protocol-specified threshold for statistical significance for <a href="https://www.benzinga.com/general/biotech/23/08/34044391/merckeisais-cancer-combo-therapy-ambition-dashed-once-again-companies-throw-towel-on-head-neck-tr" target="_blank" rel="noreferrer noopener">OS and deemed it low</a>.
In April 2023, Merck and&nbsp;Eisai discontinued the Phase 3 LEAP-003 trial, which evaluated Keytruda plus Lenvima as the first-line treatment for adults with unresectable <a target="_blank" href="https://www.benzinga.com/general/biotech/23/04/31722666/merck-eisai-shelve-keytruda-plus-lenvima-combo-trial-in-skin-cancer-setting-disappoints-in-certai" rel="noreferrer noopener">or metastatic melanoma</a>.
The decision is based on the recommendation of an independent Data Monitoring Committee, which determined that Keytruda plus Lenvima&nbsp;did not demonstrate an improvement in overall survival (OS) compared to Keytruda alone.&nbsp;
MRK Price Action: Merck stock is down 0.54% at $96.09 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43191472/broadcom-powers-solidigms-high-capacity-ssds-key-driver-for-ai-and-data-intensive-growth" target="_blank" rel="noreferrer noopener">Broadcom Powers Solidigm&#8217;s High-Capacity SSDs, A Key Driver for AI and Data-Intensive Growth</a></li>
</ul>
Photo: Romix Image via Shutterstock

Biotech

Large Cap

Health Care

ESAIY

ESALF

Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study

ADBE

On CNBC: Jim Lebenthal Buys More Adobe

Keybanc analyst Brett Fishbin maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Overweight and lowers the price target from $107 to $105.

Keybanc Maintains Overweight on Alcon, Lowers Price Target to $105

Raymond James analyst David Feaster maintains Banc of California (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BANC#NYSE">BANC</a>) with a Outperform and raises the price target from $17 to $18.

BANC

Raymond James Maintains Outperform on Banc of California, Raises Price Target to $18

Digital asset organization Alpha Transform Holdings on Friday unveiled its new investment and trading platform, the Alpha Liquid Terminal, at the WAGMI blockchain event. 
The platform, designed for institutional traders and investors, is built on a modular framework that leverages artificial intelligence (AI) to provide real-time financial intelligence.
The Alpha Liquid Terminal is designed as a multi-module platform which allows users to customize it with different features. 
The platform integrates diverse data streams, including news outlets, over-the-counter (OTC) trading platforms, centralized exchanges (CEXs), and decentralized exchanges (DEXs), and delivers all the information in one space. 
"To gain institutional trust, digital asset infrastructure must adopt traditional finance&#8217;s best practice while leveraging the technologies of decentralization and new agentic technologies," stated Enzo Villani, Founder of Alpha Liquid Terminal.
Also Read:<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43188280/heres-what-donald-trumps-crypto-czar-will-now-work-on"> Here&#8217;s What Donald Trump&#8217;s &#8216;Crypto Czar&#8217; Will Now Work On</a>
Key features include AI-powered agents that analyze market data and deliver personalized insights, trade signals, and token movement alerts. 
The platform also incorporates chatAnalyst.ai, developed to produce verifiable data across public and private companies, financial products, debt, derivatives, and digital asset markets while minimizing misinformation. 
ATH&#8217;s platform will bring in AI experts to develop this further, leveraging talent from firms such as Google, Microsoft and AWS. 
This new offering seeks to consolidate the fragmented crypto landscape to allow institutional traders to have a single platform to conduct their research and trades.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43187081/why-ethereum-now-offers-a-20-tactical-gain-10x-research">Why Ethereum Now Offers A 20% Tactical Gain: 10x Research</a></li>
</ul>
Image: Wikimedia Commons

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Alpha Transform Holdings Launches AI-Powered 'Alpha Liquid Terminal' For Digital Asset Trading

Raymond James analyst Savanthi Syth reiterates American Airlines Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) with a Outperform and lowers the price target from $24 to $23.

Raymond James Reiterates Outperform on American Airlines Gr, Lowers Price Target to $23

Benchmark analyst Michael Albanese reiterates MarineMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) with a Buy and maintains $40 price target.

Benchmark Reiterates Buy on MarineMax, Maintains $40 Price Target

WIIM

SGLY

Singularity Future Technology shares are trading lower following pricing of a registered direct offering.

Raymond James analyst Patrick O'Shaughnessy maintains Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) with a Strong Buy and raises the price target from $317 to $320.

Raymond James Maintains Strong Buy on Jones Lang LaSalle, Raises Price Target to $320

On Friday, Perspective Therapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NYSE">CATX</a>) revealed updated interim results from its ongoing Phase 1/2a trial of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43187386/perspective-therapeutics-continues-to-pursue-dose-escalation-of-212pb-vmt-net-in-its-ongoing-phase" rel="noreferrer noopener">[212Pb]VMT-α-NET</a>.
The data will be presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
The <a target="_blank" href="https://www.benzinga.com/quote/CATX" rel="noreferrer noopener">company&#8217;s</a> trial included patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors who have not received prior radiopharmaceutical therapy and whose tumors have shown radiological evidence of disease progression in the 12 months before enrollment.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41634528/positive-outlook-for-novartis-as-company-capitalizes-on-growing-treatment-opportuni" rel="noreferrer noopener">Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights</a>
Since the study&#8217;s start, no dose-limiting toxicities, grade 4 or 5 treatment-emergent adverse events, or serious adverse events have been reported.
No new grade 3 adverse events (AEs) have been observed besides the two previously reported events.
No decline in renal function was observed. Hematologic AEs such as decreased lymphocyte count and anemia were all grades 1 and 2. No treatment discontinuations due to AEs have occurred.
Further anti-tumor activities have been observed&nbsp;with a longer follow-up. As of the data cut-off date of January 10, 2025, there were two unconfirmed responses and one confirmed response, as in Cohort 2.
The patient who experienced a confirmed objective response has been in response for 17 weeks and remains in the study.
One patient was observed to experience an initial (unconfirmed) response in the fifth scan after their first dose, the first scan conducted after the end of their treatment period.
This patient experienced gradual tumor regression throughout the study, with the magnitude of change meeting the criteria for response on their most recent scan.
A third patient was observed to experience an initial (unconfirmed) response in the seventh scan after their first dose and the third scan was conducted after the end of their treatment period.
Five patients continue to have stable disease. One patient was deemed to have progressive disease after one dose by unambiguous progression of non-target lesions.
Price Action: CATX stock is up 13.1% at $4.11 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/43195763/dan-loebs-third-point-capitalizes-on-tsms-ai-expansion" target="_blank" rel="noreferrer noopener">Dan Loeb&#8217;s Third Point Capitalizes On TSM&#8217;s AI Expansion</a></li>
</ul>
Photo via Shutterstock

CATX

Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars

Raymond James analyst Patrick O'Shaughnessy downgrades CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) from Strong Buy to Outperform and lowers the price target from $155 to $152.

CBRE

Raymond James Downgrades CBRE Group to Outperform, Lowers Price Target to $152

JP Morgan analyst Samik Chatterjee <a target="_blank" href="https://www.benzinga.com/quote/QCOM/analyst-ratings" rel="noreferrer noopener">maintained an Overweight</a> rating on Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>).
Samsung Electronics recently launched its <a target="_blank" href="https://www.benzinga.com/25/01/43165472/samsung-taps-google-ai-qualcomm-tech-for-galaxy-s25-to-rival-apples-iphone" rel="noreferrer noopener">latest flagship smartphone</a>, the S25, which features Snapdragon chipsets across all variants.
This marks a share gain for Qualcomm compared to the prior generation flagship S24, where the Base and Plus models outside North America and China used Samsung&#8217;s in-house Exynos chipset.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42980720/microsoft-taps-meta-veteran-to-lead-new-coreai-division-plans-shift-from-openai-dependence" rel="noreferrer noopener">Microsoft Launches CoreAI Division: Ex-Meta Exec To Supercharge Copilot And AI Innovations</a>
Regaining this share at Samsung underscores Qualcomm&#8217;s technological leadership in mobile processors, which continues to expand into other key markets, including automotive and IoT.
Regarding the benefit from the incremental share, Chatterjee estimates the incremental revenue opportunity to amount to $2 billion within the Handset TAM and incremental EPS of about $0.63 (5% of fiscal 2025E EPS consensus).
According to Chatterjee&#8217;s estimate, incremental share gain with S25 amounts to an incremental 12 million units.&nbsp;&nbsp;
Chatterjee estimates the prior-generation flagship S24 shipments to be close to 40 million units in 2024, with 20 million for the high-end Ultra models.
With an estimated 60%/40% of the lower-end models leveraging Exynos / Snapdragon in the S24 line-up (only the U.S. and China leveraged SD), Chatterjee estimated Qualcomm had a 70% share of the last flagship, which will increase to 100% in the current generation flagship S25, or an incremental 12 million units year-on-year. The incremental units lead Chatterjee to an estimated incremental revenue of $2 billion, which implies an incremental EPS contribution of 5%.
Earlier this week, Chatterjee placed Qualcomm on Positive Catalyst Watch for the upcoming earnings print, with an upside from the expected share gain at Samsung as one of the drivers. He has already included the upside in his model.
Qualcomm stock surged 13% in the last 12 months. Investors can gain exposure to the stock through First Trust Nasdaq Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXL#NASDAQ">FTXL</a>) and iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>).
Price Action: QCOM stock is down 0.41% at $173.64 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/media/25/01/42981814/apple-and-nvidia-supplier-taiwan-semiconductor-leads-semiconductor-market-with-64-share" target="_blank" rel="noreferrer noopener">Apple And Nvidia Supplier Taiwan Semiconductor Leads Semiconductor Market with 64% Share</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

FTXL

QCOM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Qualcomm Gains $2 Billion Boost From Samsung S25 Chipset Deal, Analyst Highlights Growth in Handsets and Beyond

Benchmark analyst Fawne Jiang reiterates iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) from Hold to Hold.

Benchmark Reiterates Hold on iQIYIto Hold

Raymond James analyst Steve Moss downgrades Esquire Financial Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESQ#NASDAQ">ESQ</a>) from Strong Buy to Market Perform.

Raymond James Downgrades Esquire Financial Hldgs to Market Perform

Investors with a lot of money to spend have taken a bearish stance on Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with COST, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 19 uncommon options trades for Costco Wholesale.
This isn't normal.
The overall sentiment of these big-money traders is split between 26% bullish and 57%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $185,541, and 15 are calls, for a total amount of $1,192,636.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $600.0 to $1460.0 for Costco Wholesale during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Costco Wholesale's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Costco Wholesale's whale trades within a strike price range from $600.0 to $1460.0 in the last 30 days. 
<h3>Costco Wholesale Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737738932_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$139.6</td>
<td>$138.05</td>
<td>$139.6</td>
<td>$875.00</td>
<td>$279.2K</td>
<td align="right">323</td>
<td align="right">20</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$86.95</td>
<td>$82.0</td>
<td>$83.79</td>
<td>$1100.00</td>
<td>$192.7K</td>
<td align="right">220</td>
<td align="right">25</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$86.95</td>
<td>$82.0</td>
<td>$83.77</td>
<td>$1100.00</td>
<td>$167.5K</td>
<td align="right">220</td>
<td align="right">25</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$80.15</td>
<td>$79.25</td>
<td>$80.15</td>
<td>$940.00</td>
<td>$72.0K</td>
<td align="right">18</td>
<td align="right">1</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$179.0</td>
<td>$174.7</td>
<td>$179.0</td>
<td>$900.00</td>
<td>$71.6K</td>
<td align="right">144</td>
<td align="right">7</td>
</tr>
</tbody>
</table>

<h3>About Costco Wholesale</h3>
Costco operates a membership-based, no-frills retail model, predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given Costco's frugal cost structure, the firm is able to price its merchandise below competing retailers, driving high sales volume per warehouse and allowing the retailer to generate strong profits on thin margins. Costco operates over 600 warehouses in the United States and boasts over 60% market share in the domestic warehouse club industry. Internationally, Costco operates another 280 warehouses, primarily in markets such as Canada, Mexico, Japan, and the UK.
In light of the recent options history for Costco Wholesale, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Costco Wholesale's Current Market Status</h3>
<ul>
<li>Trading volume stands at 366,190, with COST's price down by -0.18%, positioned at $940.46.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 41 days.</li>
</ul>
<h3>What Analysts Are Saying About Costco Wholesale</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1100.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Telsey Advisory Group persists with their Outperform rating on Costco Wholesale, maintaining a target price of $1100. 
&#x2A; Consistent in their evaluation, an analyst from Telsey Advisory Group keeps a Outperform rating on Costco Wholesale with a target price of $1100. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Costco Wholesale, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

COST

Check Out What Whales Are Doing With COST

Whales with a lot of money to spend have taken a noticeably bullish stance on Marvell Tech.
Looking at options history for Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) we detected 24 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $97,873 and 21, calls, for a total amount of $1,844,050.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $106.0 to $155.0 for Marvell Tech over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Marvell Tech stands at 2513.62, with a total volume reaching 23,610.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Marvell Tech, situated within the strike price corridor from $106.0 to $155.0, throughout the last 30 days.
<h3>Marvell Tech Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737738927_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.71</td>
<td>$2.63</td>
<td>$2.64</td>
<td>$155.00</td>
<td>$343.2K</td>
<td>932</td>
<td>1.3K</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$6.85</td>
<td>$6.8</td>
<td>$6.8</td>
<td>$125.00</td>
<td>$322.3K</td>
<td>5.5K</td>
<td>512</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$2.56</td>
<td>$2.45</td>
<td>$2.56</td>
<td>$124.00</td>
<td>$128.4K</td>
<td>1.9K</td>
<td>521</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/31/25</td>
<td>$3.45</td>
<td>$3.35</td>
<td>$3.4</td>
<td>$126.00</td>
<td>$101.6K</td>
<td>576</td>
<td>452</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$37.5</td>
<td>$34.45</td>
<td>$37.5</td>
<td>$130.00</td>
<td>$97.5K</td>
<td>202</td>
<td>37</td>
</tr>
</tbody>
</table>

<h3>About Marvell Tech</h3>
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
<h3>Where Is Marvell Tech Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,068,791, the MRVL's price is up by 0.06%, now at $126.14. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 41 days.</li>
</ul>
<h3>Expert Opinions on Marvell Tech</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $139.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Marvell Tech, which currently sits at a price target of $130. 
&#x2A; Maintaining their stance, an analyst from Craig-Hallum continues to hold a Buy rating for Marvell Tech, targeting a price of $149. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Marvell Tech with a target price of $150. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Marvell Tech, which currently sits at a price target of $135. 
&#x2A; An analyst from Goldman Sachs persists with their Buy rating on Marvell Tech, maintaining a target price of $131. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Marvell Tech, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

MRVL

Looking At Marvell Tech's Recent Unusual Options Activity

Press Releases

IBN Announces Latest Episode of The Bell2Bell Podcast featuring Hank Wang, CEO of SUIC Worldwide Holdings Ltd.

SUIC Worldwide Holdings CEO Hank Wang Outlines Strategic Vision and Growth Milestones in Shareholder Letter

SUIC's I.Hart Group Opens Two Monga Stores in China, Aims for 100 in a Year and Organizes Team Targets Tri-State Area for Major U.S. Expansion

SUIC's IHart Secures Major Contracts with Taiwan French Food Group and Healthcare Giants. Expands Global Reach as US Subsidiary Gets NYC Certification to Deliver Diverse Cuisines and Automated Product Lines in the US

SUIC's Taiwan I.Hart Group Establishes Franchise Headquarters, Expands Wine Brand Retail, Scales Up Operations & Factory Production with New Equipment and Food Product Lines, Growing Distribution Channels and Sales Teams Across All 50 States

SUIC Beneway Welcomes Industry Leader Paul Fetscher as Director - President of Great American Brokerage, Esteemed Speaker, Columnist, and Chair of National Conferences, More Top Talent Joins to Accelerate Beneway's IPO Process

Former Paraguay Vice President Applauds Taiwan's Culinary Excellence at SUIC Partner iHArt's Lifekitchen and Central Kitchen, Eyes Brand Expansion to Paraguay and Global Alliances as US Industry Leaders Push for Nationwide Growth

SUIC's I.Hart Secures Key Distribution Partnerships and Signed Certified JV to Expands to Serve NYC Agencies, Airports, and Schools with Diverse Cuisine and Full Restaurant Supply Line

SUIC's I.Hart Secures Contracts with Taiwan TSMC - Global Leader in Semiconductors and Taiwan Power Company To Cater Employee Meals. Forging Strategic Partnerships with U.S. Restaurant Professionals and Suppliers to Launch Diverse Cuisine and Comprehensive Restaurant Supply Lines Nationwide

SUIC's I.Hart Partners With the World's Largest Channel and Franchisor - Shaxian Snacks Group to Promote Both Shaxian and I.Hart's Taiwanese Products to Its 100,000 Store Channels Globally

Comments

SUIC Worldwide Holdings

News

Latest news for SUIC Worldwide Holdings (OTC:SUIC) Stock

Wednesday, December 18, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga